Links for Keyword: Drug Abuse

Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.


Links 41 - 60 of 1258

By GRETCHEN REYNOLDS It’s possible that some of us are born not to run. According to an eye-opening new genetics study of lab rats, published in The Journal of Physiology, the motivation to exercise — or not — may be at least partly inherited. For years, scientists have been bedeviled by the question of why so few people regularly exercise when we know that we should. There are obvious reasons, including poor health and jammed schedules. But researchers have begun to speculate that genetics might also play a role, as some recent experiments suggest. In one, published last year, sets of fraternal and identical adult twins wore activity monitors to track their movements. The results indicated that the twins were more alike in their exercise habits than a shared upbringing alone would explain. Their willingness to work out or sit all day depended to a large extent on genetics, the researchers concluded. But which genes might be involved and how any differences in the activity of those genes might play out inside the body were mysteries. So scientists at the University of Missouri recently decided to delve into those issues by creating their own avid- or anti-exercising animals. They accomplished this task by inter-breeding normal rats that had voluntarily run on wheels in the lab. The male rats that had run the most were bred with the female rats that also had run the most; those that had run the least were likewise mated. This scheme continued through many generations, until the scientists had two distinct groups of rats, some of which would willingly spend hours on running wheels, while the others would skitter on them only briefly, if at all. In their first experiments with these rats, the researchers found some intriguing differences in the activity of certain genes in their brains. In normal circumstances, these genes create proteins that tell young cells to grow up and join the working world. But if the genes don’t function normally, the cells don’t receive the necessary chemical messages and remain in a prolonged, feckless cellular adolescence. Such immature cells cannot join the neural network and don’t contribute to healthy brain function. © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19470 - Posted: 04.10.2014

By SABRINA TAVERNISE Federal health regulators approved a drug overdose treatment device on Thursday that experts say will provide a powerful lifesaving tool in the midst of a surging epidemic of prescription drug abuse. Similar to an EpiPen used to stop allergic reactions to bee stings, the easy-to-use injector — small enough to tuck into a pocket or a medicine cabinet — can be used by the relatives or friends of people who have overdosed. The hand-held device, called Evzio, delivers a single dose of naloxone, a medication that reverses the effects of an overdose, and will be used on those who have stopped breathing or lost consciousness from an opioid drug overdose. Naloxone is the standard treatment in such circumstances, but until now, has been available mostly in hospitals and other medical settings, when it is often used too late to save the patient. The decision to quickly approve the new treatment, which is expected to be available this summer, comes as deaths from opioids continue to mount, including an increase in those from heroin, which contributed to the death of the actor Philip Seymour Hoffman in February. Federal health officials, facing criticism for failing to slow the rising death toll, are under pressure to act, experts say. “This is a big deal, and I hope gets wide attention,” said Dr. Carl R. Sullivan III, director of the addictions program at West Virginia University. “It’s pretty simple: Having these things in the hands of people around drug addicts just makes sense because you’re going to prevent unnecessary mortality.” The scourge of drug abuse has battered states across the country, with deaths from overdoses now outstripping those from traffic crashes. Prescription drugs alone now account for more than half of all drug overdose deaths, and one major category of them, opioids, or painkillers, take the lives of more Americans than heroin and cocaine combined. Deaths from opioids have quadrupled in 10 years to more than 16,500 in 2010, according to federal data. © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 8: General Principles of Sensory Processing, Touch, and Pain
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 5: The Sensorimotor System
Link ID: 19446 - Posted: 04.05.2014

By ABIGAIL ZUGER, M.D. One legend says it all began when a North African herder saw his goats eat some wild berries, then frolic with unusual verve. Another story cites a few small leaves blown off a nearby bush into the Chinese emperor’s mug of hot water. Either way, whether caffeine entered the life of man by coffee bean or tea leaf, happiness ensued. Happiness, that is, for all but the poor souls charged with saving us from our drugs, for no regulatory challenge trumps the one posed by caffeine, molecule of elegant enjoyment and increasing abuse, man’s best friend and occasional killer. As Murray Carpenter makes clear in his methodical review, our society’s metrics are no match for this substance’s nuances, whether among athletes, teenagers, experimental subjects or the average dependent Joe. (Read an excerpt of “Caffeinated.”) Pure caffeine is a bitter white powder. In the body it blocks the effects of the molecule adenosine, a crucial brake on many physiologic processes. With just enough caffeine in the system, the body’s organs become a little more themselves: the brain a little brainier, the muscles a little springier, the blood vessels a little tighter, the digestion a little more efficient. With too much caffeine, all can accelerate into cardiac arrest. It takes only about 30 milligrams of caffeine (less than a cup of coffee or can of cola) for stimulative effects to be noticeable. A hundred milligrams a day will hook most people: They feel immensely unhappy without their daily fix, and the organs all whine in protest for a few days. It takes more than 10 grams to kill you — a dose impossible to achieve with traditional beverages alone. However, the new caffeine-rich energy shots make it alarmingly easy for party-minded people to achieve the zone between enough and much too much. © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19427 - Posted: 03.31.2014

Daniel Cressey The controversy over electronic cigarettes has been reignited today with the publication of a study claiming that they do not help smokers to quit their habit. Whether or not ‘e-cigarettes’ are an effective aid in the cessation of smoking has become a major issue for the rapidly growing industry that produces the devices, and for the tobacco researchers struggling to assess their impact. There is widespread agreement that inhaling from an e-cigarette, where a heating element vapourizes a liquid containing nicotine, is not as harmful as smoking a conventional cigarette, and proponents say that the products could save millions of lives. But some researchers and tobacco-control activists fear that the devices could make tobacco use seem socially acceptable again and may not assist people in actually reducing their addiction. Pamela Ling, a tobacco researcher at the University of California, San Francisco, and her colleagues followed 949 people who detailed their smoking habits though an online survey, and found that 88 of those who had used e-cigarettes were no more likely to have quit or reduced their smoking after a year than other smokers. “We found that there was no difference in the rate of quitting between smokers who used an e-cigarette and those who did not”, even after controlling for factors such as the user's dependence on tobacco, Ling told Nature in an e-mail. She added: “Advertising suggesting that e-cigarettes are effective for smoking cessation should be prohibited until such claims are supported by scientific evidence.” Her team reports the results today in JAMA Internal Medicine1. © 2014 Nature Publishing Group

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19405 - Posted: 03.25.2014

By MATT RICHTEL A dangerous new form of a powerful stimulant is hitting markets nationwide, for sale by the vial, the gallon and even the barrel. The drug is nicotine, in its potent, liquid form — extracted from tobacco and tinctured with a cocktail of flavorings, colorings and assorted chemicals to feed the fast-growing electronic cigarette industry. These “e-liquids,” the key ingredients in e-cigarettes, are powerful neurotoxins. Tiny amounts, whether ingested or absorbed through the skin, can cause vomiting and seizures and even be lethal. A teaspoon of even highly diluted e-liquid can kill a small child. But, like e-cigarettes, e-liquids are not regulated by federal authorities. They are mixed on factory floors and in the back rooms of shops, and sold legally in stores and online in small bottles that are kept casually around the house for regular refilling of e-cigarettes. Evidence of the potential dangers is already emerging. Toxicologists warn that e-liquids pose a significant risk to public health, particularly to children, who may be drawn to their bright colors and fragrant flavorings like cherry, chocolate and bubble gum. “It’s not a matter of if a child will be seriously poisoned or killed,” said Lee Cantrell, director of the San Diego division of the California Poison Control System and a professor of pharmacy at the University of California, San Francisco. “It’s a matter of when.” © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19399 - Posted: 03.24.2014

By Ariana Eunjung Cha, Millions of ordinary Americans are now able to walk into a marijuana dispensary and purchase bags of pot on the spot for a variety of medical ailments. But if you’re a researcher like Sue Sisley, a psychiatrist who studies post- traumatic stress disorder, getting access to the drug isn’t nearly so easy. That’s because the federal government has a virtual monopoly on growing and cultivating marijuana for scientific research, and getting access to the drug requires three separate levels of approval. Marijuana offers hope for 6-year-old girl with rare condition: In marijuana, Lydia Schaeffer’s family members think they might have found a treatment that works. Now, they are trying to help legalize the drug. Sisley’s fight to get samples for her study — now in its fourth month — illuminates the complex politics of marijuana in the United States. While 20 states and the District have made medical marijuana legal — in Colorado and Washington state the drug is also legal for recreational use — it remains among the most tightly controlled substances under federal law. For scientists, that means extra steps to obtain, transport and secure the drug — delays they say can slow down their research by months or even years. © 1996-2014 The Washington Post

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 16: Psychopathology: Biological Basis of Behavior Disorders
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 12: Psychopathology: Biological Basis of Behavioral Disorders
Link ID: 19396 - Posted: 03.22.2014

by Bruce Bower Actor Philip Seymour Hoffman’s February death from a drug overdose triggered media reports blaming the terrible disease of addiction for claiming another life. But calling addiction a “disease” may be misguided, according to an alternative view with some scientific basis. Most people who are addicted to cigarette smoking, alcohol or other drugs manage to quit, usually on their own, after experiencing major attitude adjustments. Although relapses occur, successes ultimately outnumber fatalities. People can permanently walk away from addiction. Evidence that addiction is a solvable coping problem rather than a chronic, recurring disease seems like encouraging news. But it’s highly controversial. Neuroscientists and many clinicians regard drug addictions as brain illnesses best vanquished with the help of medications that fight cravings and withdrawal. From this perspective, drug-induced brain changes increase a person’s thirst for artificial highs and make quitting progressively more difficult. This conflict over addiction’s nature plays out in two lines of research: studies of remission and relapse among treated substance abusers and long-term studies of the general population. Follow-up investigations of people who attend treatment programs report that addicts never completely shake an urge to snort, inject, guzzle or otherwise consume their poisons of choice. Ongoing treatment in psychotherapy, rehab centers or 12-step groups encourages temporary runs of sobriety, but it’s easier to kick the bucket than to kick the habit. Surveys and long-term studies of the general population, however, observe that addicts typically spend their youth in a substance-induced haze but drastically cut back or quit using drugs altogether by early adulthood. Most of those who renounce the “high” life do so without formal treatment. © Society for Science & the Public 2000 - 2013.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19332 - Posted: 03.08.2014

By SABRINA TAVERNISE Middle and high school students who used electronic cigarettes were more likely to smoke real cigarettes and less likely to quit than students who did not use the devices, a new study has found. They were also more likely to smoke heavily. But experts are divided about what the findings mean. The study’s lead author, Stanton Glantz, a professor of medicine at the University of California, San Francisco, who has been critical of the devices, said the results suggested that the use of e-cigarettes was leading to less quitting, not more. “The use of e-cigarettes does not discourage, and may encourage, conventional cigarette use among U.S. adolescents,” the study concluded. It was published online in the journal JAMA Pediatrics on Thursday. But other experts said the data did not support that interpretation. They said that just because e-cigarettes are being used by youths who smoke more and have a harder time quitting does not mean that the devices themselves are the cause of those problems. It is just as possible, they said, that young people who use the devices were heavier smokers to begin with, or would have become heavy smokers anyway. “The data in this study do not allow many of the broad conclusions that it draws,” said Thomas J. Glynn, a researcher at the American Cancer Society. The study is likely to stir the debate further over what electronic cigarettes mean for the nation’s 45 million smokers, about three million of whom are middle and high school students. Some experts worry that e-cigarettes are a gateway to smoking real cigarettes for young people, though most say the data is too skimpy to settle the issue. Others hope the devices could be a path to quitting. So far, the overwhelming majority of young people who use e-cigarettes also smoke real cigarettes, a large federal survey published last year found. Still, while e-cigarette use among youths doubled from 2011 to 2012, regular cigarette smoking for youths has continued to decline. The rate hit a record low in 2013 of 9.6 percent, down by two-thirds from its peak in 1997. © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19331 - Posted: 03.08.2014

The teenager's brain has a lot of developing to do: It must transform from the brain of a child into the brain of an adult. Some researchers worry how marijuana might affect that crucial process. "Actually, in childhood our brain is larger," says , director of the brain imaging and neuropsychology lab at University of Wisconsin, Milwaukee. "Then, during the teenage years, our brain is getting rid of those connections that weren't really used, and it prunes back. "It actually makes the brain faster and more efficient." The streamlining process ultimately helps the brain make judgments, think critically and remember what it has learned. Lisdahl says it's a mistake for teenagers to use cannabis. "It's the absolute worst time," she says, because the mind-altering drug can disrupt development. Think of the teen years, she says, as the "last golden opportunity to make the brain as healthy and smart as possible." Lisdahl points to a growing number of that show regular marijuana use — once a week or more — actually changes the structure of the teenage brain, specifically in areas dealing with memory and problem solving. That can affect cognition and academic performance, she says. "And, indeed, we see, if we look at actual grades, that chronic marijuana-using teens do have, on average, one grade point lower than their matched peers that don't smoke pot," Lisdahl says. ©2014 NPR

Related chapters from BP7e: Chapter 7: Life-Span Development of the Brain and Behavior; Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 13: Memory, Learning, and Development; Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19320 - Posted: 03.04.2014

By Ariana Eunjung Cha, Standing in a Wisconsin State Capitol hearing room surrounded by parents hugging their seriously ill children, Sally Schaeffer began to cry as she talked about her daughter. Born with a rare chromosomal disorder, 6-year-old Lydia suffers from life-threatening seizures that doctors haven’t been able to control despite countless medications. The family’s last hope: medical marijuana. Schaeffer, 39, didn’t just ask lawmakers to legalize the drug. She begged. “If it was your child and you didn’t have options, what would you do?” she said during her testimony in Madison on Feb. 12. The representatives were so moved that they introduced a bipartisan bill to allow parents in situations similar to Schaeffer’s to use the drug on their children. Emboldened by stories circulated through Facebook, Twitter and the news media about children with seizure disorders who have been successfully treated with a special oil extract made from cannabis plants, mothers have become the new face of the medical marijuana movement. Similar scenes have been playing out in recent weeks in other states where medical marijuana remains illegal: Oklahoma, Florida, Georgia, Utah, New York, North Carolina, Alabama, Kentucky. The “mommy lobby” has been successful at opening the doors to legalizing marijuana — if only a crack, in some places — where others have failed. In the 1970s and ’80s, mothers were on the other side of the issue, successfully fending off efforts to decriminalize marijuana with heartbreaking stories about how their teenage children’s lives unraveled when they began to use the drug. © 1996-2014 The Washington Post

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 3: Neurophysiology: The Generation, Transmission, and Integration of Neural Signals
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 3: Neurophysiology: The Generation, Transmission, and Integration of Neural Signals
Link ID: 19314 - Posted: 03.03.2014

By SABRINA TAVERNISE Dr. Michael Siegel, a hard-charging public health researcher at Boston University, argues that e-cigarettes could be the beginning of the end of smoking in America. He sees them as a disruptive innovation that could make cigarettes obsolete, like the computer did to the typewriter. But his former teacher and mentor, Stanton A. Glantz, a professor of medicine at the University of California, San Francisco, is convinced that e-cigarettes may erase the hard-won progress achieved over the last half-century in reducing smoking. He predicts that the modern gadgetry will be a glittering gateway to the deadly, old-fashioned habit for children, and that adult smokers will stay hooked longer now that they can get a nicotine fix at their desks. These experts represent the two camps now at war over the public health implications of e-cigarettes. The devices, intended to feed nicotine addiction without the toxic tar of conventional cigarettes, have divided a normally sedate public health community that had long been united in the fight against smoking and Big Tobacco. The essence of their disagreement comes down to a simple question: Will e-cigarettes cause more or fewer people to smoke? The answer matters. Cigarette smoking is still the single largest cause of preventable death in the United States, killing about 480,000 people a year. Dr. Siegel, whose graduate school manuscripts Dr. Glantz used to read, says e-cigarette pessimists are stuck on the idea that anything that looks like smoking is bad. “They are so blinded by this ideology that they are not able to see e-cigarettes objectively,” he said. Dr. Glantz disagrees. “E-cigarettes seem like a good idea,” he said, “but they aren’t.” © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19284 - Posted: 02.24.2014

By MAGGIE KOERTH-BAKER If you are pulled over on suspicion of drunken driving, the police officer is likely to ask you to complete three tasks: Follow a pen with your eyes while the officer moves it back and forth; get out of the car and walk nine steps, heel to toe, turn on one foot and go back; and stand on one leg for 30 seconds. Score well on all three of these Olympic events, and there’s a very good chance that you are not drunk. This so-called standard field sobriety test has been shown to catch 88 percent of drivers under the influence of alcohol. But it is nowhere near as good at spotting a stoned driver. In a 2012 study published in the journal Psychopharmacology, only 30 percent of people under the influence of THC, the active ingredient in marijuana, failed the field test. And its ability to identify a stoned driver seems to depend heavily on whether the driver is accustomed to being stoned. A 21-year-old on his first bender and a hardened alcoholic will both wobble on one foot. But the same is not necessarily true of a driver who just smoked his first joint and the stoner who is high five days a week. In another study, 50 percent of the less frequent smokers failed the field test. As more states legalize medical and recreational marijuana, distinctions like these will grow more and more important. But science’s answers to crucial questions about driving while stoned — how dangerous it is, how to test for impairment, and how the risks compare to driving drunk — have been slow to reach the general public. “Our goal is to put out the science and have it used for evidence-based drug policy,” said Marilyn A. Huestis, a senior investigator at the National Institute on Drug Abuse. “But I think it’s a mishmash.” © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19260 - Posted: 02.18.2014

By Brian Palmer, The death of Philip Seymour Hoffman this month has raised many questions about drug addiction, among them: What do drugs such as heroin do to the brain to make them so addictive? Can these chemical changes be undone? Over the past 20 years, research into drug addiction has identified several chemical and physical changes to the brain brought on by addictive substances. There is a wad of nerve cells in the central part of your brain, measuring about half an inch across, called the nucleus accumbens. When you eat a doughnut, have sex or do something else that your brain associates with survival and breeding, this region is inundated with dopamine, a neurotransmitter. This chemical transaction is partly responsible for the experience of pleasure you get from these activities. Drugs such as heroin also trigger this response, but the dopamine surge from drugs is faster and long-lasting. When a person repeatedly subjects his nucleus accumbens to this narcotic-induced flood, the nerve cells that dopamine acts upon become exhausted from stimulation. The brain reacts by dampening its dopamine response — not just to heroin or cocaine, but probably to all forms of pleasurable behavior. In addition, some of the receptors themselves appear to die off. As a result, hyper-stimulating drugs become the only way to trigger a palpable dopamine response. Drug addicts seek larger and larger hits to achieve an ever-diminishing pleasure experience, and they have trouble feeling satisfaction from the things that healthy people enjoy. Behavioral conditioning also plays a role. Once your brain becomes accustomed to the idea that eating a doughnut or having sex will provide pleasure, just seeing a doughnut or an attractive potential mate triggers the dopamine cascade into the nucleus accumbens. That’s part of the reason it is so difficult for recovering drug addicts to stay clean over the long term. Sights, sounds and smells associated with the drug high — needles, for example, or the friends with whom they used to get high — prime this dopamine response, and the motivation to seek the big reward of a drug hit builds. © 1996-2014 The Washington Post

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19259 - Posted: 02.18.2014

By Ben Cimons, Recently I received an e-mail from my mother with a link to the harrowing tale of a 16-year-old Northern Virginia girl who overdosed on heroin and died, and whose companions had dumped her body. My mom wrote that she found the story “terrifying, because that easily could have been you. I thank God every day that it wasn’t, and that you are safe and healthy.’’ She was right. It could have been me, and it very nearly was. The only difference was that after I passed out from an accidental heroin overdose, the person I was with called 911 before abandoning me. Today I am 23 years old, living in a recovery house in Wilmington, N.C., and slowly regaining my life. But it has not been easy. Heroin is seductive. The minute it hits you, all your worries disappear. You are content with everything. You feel warm. You can’t help but smile. You feel free. The first time I tried it, I found an escape from the feelings of sadness and isolation I had been experiencing for as long as I could remember. But once heroin gets a hold on you, it never lets go. Heroin has been in the news a lot lately, most recently because of the death, apparently by overdose, of actor Philip Seymour Hoffman. Heroin is everywhere. It’s easy to find, including in the suburbs where I lived until recently, and cheaper than prescription pills. © 1996-2014 The Washington Post

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19244 - Posted: 02.13.2014

By DEBORAH SONTAG HUDSON, Wis. — Karen Hale averts her eyes when she drives past the Super 8 motel in this picturesque riverfront town where her 21-year-old daughter, Alysa Ivy, died of an overdose last May. She has contemplated asking the medical examiner, now a friend, to accompany her there so she could lie on the bed in Room 223 where her child’s body was found. But Ms. Hale, 52, is not ready, just as she is not ready to dismantle Ms. Ivy’s bedroom, where an uncapped red lipstick sits on the dresser and a teddy bear on the duvet. The jumble of belongings both comforts and unsettles her — colorful bras, bangle bracelets and childhood artwork; court summonses; a 12-step bible; and a Hawaiian lei, bloodstained, that her daughter used as a tourniquet for shooting heroin into her veins. “My son asked me not to make a shrine for her,” Ms. Hale said. “But I don’t know what to do with her room. I guess on some level I’m still waiting for her to come home. I’d be so much more empathetic now. I used to take it personal, like she was doing this to me and I was a victim.” When the actor Philip Seymour Hoffman died with a needle in his arm on Feb. 2, Ms. Hale thought first about his mother, then his children. Few understand the way addiction mangles families, she said, and the rippling toll of the tens of thousands of fatal heroin and painkiller overdoses every year. Perhaps it took Mr. Hoffman’s death, she said, to “wake up America to all the no-names who passed away before him,” leaving a cross-country trail of bereavement. © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19235 - Posted: 02.11.2014

By Joel Achenbach, The death last Sunday of Oscar-winning actor Philip Seymour Hoffman at age 46 focused media attention on the nationwide surge in heroin use and overdoses. But the very real heroin epidemic is framed by an even more dramatic increase since the beginning of the century in overdoses from pharmaceutical drugs known as opioids. These are, in effect, tandem epidemics — an addiction crisis driven by the powerful effects on the human brain of drugs derived from morphine. Prescription opioids are killing Americans at more than five times the rate that heroin is, according to the most recent numbers from the Centers for Disease Control and Prevention. These drugs are sold under such familiar brand names as OxyContin, Vicodin and Percocet and can be found in medicine cabinets in every precinct of American society. They’re also sold illicitly on the street or crushed and laced into heroin. There have been numerous efforts by law enforcement agencies to crack down on “pill mills” that dispense massive amounts of the pharmaceuticals, as well as regulations aimed at preventing users from “doctor shopping” to find someone who will write a prescription. Those efforts have had the unintended effect, officials say, of driving some people to heroin in recent years as their pill supply dries up. © 1996-2014 The Washington Post

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19218 - Posted: 02.08.2014

|By Carl Erik Fisher After 22 years of failed treatments, including rehabilitation, psychotherapy and an array of psychiatric medications, a middle-aged Dutch man decided to take an extraordinary step to fight his heroin addiction. He underwent an experimental brain surgery called deep brain stimulation (DBS). At the University of Amsterdam, researchers bored small holes in his skull and guided two long, thin probes deep into his head. The ends of the probes were lined with small electrodes, which were positioned in his nucleus accumbens, a brain area near the base of the skull that is associated with addiction. The scientists ran the connecting wires under his scalp, behind his ear and down to a battery pack sewn under the skin of his chest. Once turned on, the electrodes began delivering constant electrical pulses, much like a pacemaker, with the goal of altering the brain circuits thought to be causing his drug cravings. At first the stimulation intensified his desire for heroin, and he almost doubled his drug intake. But after the researchers adjusted the pulses, the cravings diminished, and he drastically cut down his heroin use. Neurosurgeries are now being pursued for a variety of mental illnesses. Initially developed in the 1980s to treat movement disorders, including Parkinson's disease, DBS is today used to treat depression, dementia, obsessive-compulsive disorder, substance abuse and even obesity. Despite several success stories, many of these new ventures have attracted critics, and some skeptics have even called for an outright halt to this research. © 2014 Scientific American

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 11: Motor Control and Plasticity
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 5: The Sensorimotor System
Link ID: 19216 - Posted: 02.06.2014

By Deborah Kotz / Globe Staff Public health officials, politicians, and smoking researchers cheered the Wednesday announcement from CVS Caremark that they will stop selling cigarettes and other tobacco products at CVS pharmacy stores by October. President Obama, a former smoker, said CVS is setting a “powerful example” and that will help public health efforts to reduce smoking-related deaths and illnesses. The American Public Health Association called it a “historic decision,” and the American Association of Cancer Research called it a “visionary move.” Dozens of other anti-smoking organizations and medical organizations—whose physicians treat the lung cancer, emphysema, and heart disease caused by smoking—proferred their approval and hope that other big chain pharmacies would follow suit. “CVS made a very compelling argument today that if you’re in the business of healthcare, you shouldn’t be in the business of selling tobacco products,” said Vince Willmore, spokesperson for the Campaign for Tobacco-Free Kids. “We’ll be taking that argument to every store with a pharmacy to make sure this is a catalyst for them.” Whether the CVS decision will result in fewer smokers remains unknown, said Margaret Reid, who directs tobacco control efforts at the Boston Public Health Commission, but added that it will certainly make tobacco products less readily available to smokers. When Boston implemented a ban on tobacco sales in pharmacies five years ago, it resulted in 85 fewer tobacco retailers in the city—about a 10 percent drop in the number of places permitted to sell cigarettes, cigars, and chewing tobacco. © 2014 Boston Globe Media Partners, LLC

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19213 - Posted: 02.06.2014

By JANE E. BRODY “Even 50 years after the first surgeon general’s report on smoking and health, we’re still finding out new ways that tobacco kills and maims people,” Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention, recently told me. “It’s astonishing how bad it is.” Dr. Frieden and public health specialists everywhere are seeking better ways to help the 44 million Americans who still smoke to quit and to keep young people from getting hooked on cigarettes. “Fewer than 2 percent of doctors smoke. Why can’t we get to that rate in society as a whole?” he wondered. One reason: Smoking rates are highest among the poor, poorly educated and people with mental illness, populations hard to reach with educational messages and quit-smoking aids. But when I mentioned to Dr. Frieden, a former New York City health commissioner, that the city’s streets are filled with young adult smokers who appear to be well educated and well dressed, he said television seems to have had an outsize influence. Focus groups of white girls in New York private schools have suggested a “Sex in the City” effect, he said: Girls think smoking makes them look sexy. In the last two years, middle-aged men, too, have begun smoking in increasing numbers after a half-century decline. Dr. Frieden cited “Mad Men,” the popular TV series featuring admen in the early 1960s, when well over half of American men smoked. Dr. Frieden said that an antismoking effort begun in 2008 by the World Health Organization “can make a huge difference in curbing smoking, and we should fully implement what we know works.” The program is called Mpower: © 2014 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 19170 - Posted: 01.27.2014

By Roni Jacobson Over the past 10 years the number of overdose deaths from prescription painkillers—also known as opioid analgesics—has tripled, from 4,000 people in 1999 to more than 15,000 people every year in the U.S. today. Prescription pain medication now causes more overdose deaths than heroin and cocaine combined. In 2010 one in 20 Americans older than age 12 reported taking painkillers recreationally; some steal from pharmacies or buy them from a dealer, but most have a doctor's prescription or gain access to pills through friends and relatives. Yet millions of people legitimately rely on these medications to cope with the crippling pain they face every day. How do we make sure prescription opioids are readily available to those who depend on them for medical relief but not so available that they become easily abused? Here we break down the steps taken at various levels—and the experts' recommendations for future interventions—to curb prescription opioid addiction and overdose in the U.S. © 2014 Scientific American

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 8: General Principles of Sensory Processing, Touch, and Pain
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 5: The Sensorimotor System
Link ID: 19159 - Posted: 01.22.2014